Business Standard

Parenteral Drugs (India) reports standalone net loss of Rs 44.17 crore in the March 2017 quarter

Image

Capital Market

Sales decline 43.81% to Rs 10.31 crore

Net Loss of Parenteral Drugs (India) reported to Rs 44.17 crore in the quarter ended March 2017 as against net loss of Rs 39.27 crore during the previous quarter ended March 2016. Sales declined 43.81% to Rs 10.31 crore in the quarter ended March 2017 as against Rs 18.35 crore during the previous quarter ended March 2016.

For the full year,net loss reported to Rs 113.31 crore in the year ended March 2017 as against net loss of Rs 108.49 crore during the previous year ended March 2016. Sales declined 64.92% to Rs 52.19 crore in the year ended March 2017 as against Rs 148.78 crore during the previous year ended March 2016.

 
ParticularsQuarter EndedYear EndedMar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var.Sales10.3118.35 -44 52.19148.78 -65 OPM %-191.56-181.53 --61.49-30.58 - PBDT-38.47-50.68 24 -106.03-103.50 -2 PBT-42.71-51.97 18 -125.13-120.56 -4 NP-44.17-39.27 -12 -113.31-108.49 -4

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 02 2017 | 4:12 PM IST

Explore News